{"product_id":"panitumumabpanitumumab-панитумумаб-panitumumab","title":"Panitumumab(Panitumumab)          панитумумаб (Panitumumab)","description":"\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003ePanitumumab (Panitumumab)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e is a recombinant fully human monoclonal antibody and targeted anticancer medicine. It binds to the \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eepidermal growth factor receptor (EGFR)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e on the surface of cancer cells, inhibiting EGFR signaling involved in tumor cell growth and proliferation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eIndications:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Panitumumab is primarily used to treat certain patients with \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003emetastatic colorectal cancer (mCRC)\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e, particularly tumors that are \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eRAS wild-type\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e. It may be used alone or in combination with other anticancer therapies, depending on the treatment regimen.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eDosage form:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Concentrate or solution for intravenous infusion, depending on the specific product.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003eAdministration:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Administered by \u003c\/span\u003e\u003cstrong\u003e\u003cspan\u003eintravenous infusion\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e under the supervision of a qualified healthcare professional.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"isSelectedEnd\"\u003e\u003cstrong\u003e\u003cspan\u003ePossible adverse effects:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Common adverse reactions include skin rash, dermatitis, diarrhea, fatigue, nausea, and infusion-related reactions. Electrolyte abnormalities, particularly low magnesium levels, may also occur.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eImportant:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan\u003e Panitumumab is a prescription oncology medicine and should be used under appropriate medical supervision. RAS mutation status should be determined before treatment when required by the applicable treatment guidelines and product labeling.\u003c\/span\u003e\u003c\/p\u003e","brand":"XOMEDS","offers":[{"title":"Default Title","offer_id":45404446195755,"sku":null,"price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-12-2597-280x280.jpg?v=1789726914","url":"https:\/\/xomeds.com\/ru\/products\/panitumumabpanitumumab-%d0%bf%d0%b0%d0%bd%d0%b8%d1%82%d1%83%d0%bc%d1%83%d0%bc%d0%b0%d0%b1-panitumumab","provider":"XOMEDS","version":"1.0","type":"link"}